Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 1690474, 19 pages
http://dx.doi.org/10.1155/2016/1690474
Research Article

The Protective Effect of Beraprost Sodium on Diabetic Nephropathy by Inhibiting Inflammation and p38 MAPK Signaling Pathway in High-Fat Diet/Streptozotocin-Induced Diabetic Rats

1Department of Endocrinology, Nanjing General Hospital of Nanjing Military Command (Jinling Hospital), 305 East Zhongshan Road, Nanjing, Jiangsu 210002, China
2Department of Endocrinology, Shanghai Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China

Received 23 September 2015; Revised 10 November 2015; Accepted 16 November 2015

Academic Editor: Francesco Perticone

Copyright © 2016 Li Peng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ahmad, “Management of diabetic nephropathy: recent progress and future perspective,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 9, no. 4, pp. 343–358, 2015. View at Publisher · View at Google Scholar
  2. J. Guan, L. Long, Y.-Q. Chen et al., “Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy,” Genetics and Molecular Research, vol. 13, no. 2, pp. 4154–4158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Watanabe, H. Nakashima, S. Mochizuki et al., “Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I2 analog, beraprost sodium,” American Journal of Nephrology, vol. 30, no. 1, pp. 1–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Cargnello and P. P. Roux, “Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases,” Microbiology and Molecular Biology Reviews, vol. 75, no. 1, pp. 50–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. Park, C. S. Bae, S. K. Lim et al., “Effect of protopanaxadiol derivatives in high glucose-induced fibronectin expression in primary cultured rat mesangial cells: role of mitogen-activated protein kinases and Akt,” Archives of Pharmacal Research, vol. 33, no. 1, pp. 151–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. K. Wong, A. W. Y. Ho, P. C. Y. Tong et al., “Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy,” Clinical and Experimental Immunology, vol. 149, no. 1, pp. 123–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Toyoda, D. Suzuki, M. Honma et al., “High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy,” Kidney International, vol. 66, no. 3, pp. 1107–1114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Zarubin and J. Han, “Activation and signaling of the p38 MAP kinase pathway,” Cell Research, vol. 15, no. 1, pp. 11–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Ren, Y. Shi, Y. Wang et al., “p38 MAPK pathway is involved in high glucose-induced thioredoxin interacting protein induction in mouse mesangial cells,” FEBS Letters, vol. 584, no. 15, pp. 3480–3485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Verzola, M. T. Gandolfo, F. Ferrario et al., “Apoptosis in the kidneys of patients with type II diabetic nephropathy,” Kidney International, vol. 72, no. 10, pp. 1262–1272, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-J. Lu, T.-F. Tzeng, S.-S. Liou, S. D. Lin, M.-C. Wu, and I.-M. Liu, “Polysaccharides from Liriopes Radix ameliorate streptozotocin-induced type I diabetic nephropathy via regulating NF-κB and p38 MAPK signaling pathways,” BMC Complementary and Alternative Medicine, vol. 14, article 156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Komers, J. N. Lindsley, T. T. Oyama, D. M. Cohen, and S. Anderson, “Renal p38 MAP kinase activity in experimental diabetes,” Laboratory Investigation, vol. 87, no. 6, pp. 548–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. Z.-M. Lv, Q. Wang, Q. Wan et al., “The role of the p38 MAPK signaling pathway in high glucose-induced epithelial-mesenchymal transition of cultured human renal tubular epithelial cells,” PLoS ONE, vol. 6, no. 7, Article ID e22806, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. C. A. Duyndam, S. T. M. Hulscher, E. Van der Wall, H. M. Pinedo, and E. Boven, “Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite,” The Journal of Biological Chemistry, vol. 278, no. 9, pp. 6885–6895, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. D. R. Tomlinson, “Mitogen-activated protein kinases as glucose transducers for diabetic complications,” Diabetologia, vol. 42, no. 11, pp. 1271–1281, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Lièvre, S. Morand, B. Besse, J.-N. Fiessinger, and J.-P. Boissel, “Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial,” Circulation, vol. 102, no. 4, pp. 426–431, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Nasrallah and R. L. Hébert, “Prostacyclin signaling in the kidney: implications for health and disease,” American Journal of Physiology—Renal Physiology, vol. 289, no. 2, pp. F235–F246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Sato, M. Kaneko, M. Tamura, and H. Kurumatani, “The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats,” Diabetes, vol. 59, no. 4, pp. 1092–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. L.-Y. Zhang, J.-J. Zou, and Z.-M. Liu, “Effects of beraprost sodium, a prostaglandin I2 analog, on high glucose-induced proliferation and oxidative stress in a rat glomerular mesangial cell line,” Pharmacology, vol. 87, no. 5-6, pp. 350–358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Ha and H. B. Lee, “Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney,” Nephrology, vol. 10, supplement s2, pp. S7–S10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. Houliston, J. D. Pearson, and C. P. D. Wheeler-Jones, “Agonist-specific cross talk between ERKs and p38mapk regulates PGI2 synthesis in endothelium,” American Journal of Physiology—Cell Physiology, vol. 281, no. 4, pp. C1266–C1276, 2001. View at Google Scholar · View at Scopus
  22. T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the comparative CT method,” Nature Protocols, vol. 3, no. 6, pp. 1101–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Skovsø, “Modeling type 2 diabetes in rats using high fat diet and streptozotocin,” Journal of Diabetes Investigation, vol. 5, no. 4, pp. 349–358, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-H. Hu, T. Jiang, S.-S. Yang, and Y. Yang, “Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes,” Experimental and Clinical Endocrinology & Diabetes, vol. 121, no. 4, pp. 220–224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Guo, R. Zhang, J. Li, and G. Xu, “Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adenine dinucleotide phosphate oxidase in the heart and aorta in type 2 diabetic rats,” Cardiovascular Diabetology, vol. 11, no. 1, article 94, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Watanabe, H. Nakashima, K. Ito, K. Miyake, and T. Saito, “Improvement of dyslipidemia in OLETF rats by the prostaglandin I2 analog beraprost sodium,” Prostaglandins and Other Lipid Mediators, vol. 93, no. 1-2, pp. 14–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. L. N. Wang, Z. Tang, I. Shou, M. Fukui, and Y. Tomino, “Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes,” Nephron, vol. 73, no. 4, pp. 637–643, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Fioretto and M. Mauer, “Histopathology of diabetic nephropathy,” Seminars in Nephrology, vol. 27, no. 2, pp. 195–207, 2007. View at Publisher · View at Google Scholar
  29. E. N. Obineche, E. Mensah-Brown, S. I. Chandranath, I. Ahmed, O. Naseer, and A. Adem, “Morphological changes in the rat kidney following long-term diabetes,” Archives of Physiology and Biochemistry, vol. 109, no. 3, pp. 241–245, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Li and J. F. Bertram, “Review: endothelial-myofibroblast transition, a new player in diabetic renal fibrosis,” Nephrology, vol. 15, no. 5, pp. 507–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. C. Harris and E. G. Neilson, “Toward a unified theory of renal progression,” Annual Review of Medicine, vol. 57, pp. 365–380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Yamamoto, Y. Maeshima, H. Kitayama et al., “Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy,” Diabetes, vol. 53, no. 7, pp. 1831–1840, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Okonogi, M. Nishimura, Y. Utsunomiya et al., “Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus,” Clinical Nephrology, vol. 55, no. 5, pp. 357–364, 2001. View at Google Scholar · View at Scopus
  34. B. T. Lee, F. A. Ahmed, L. L. Hamm et al., “Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease,” BMC Nephrology, vol. 16, article 77, 2015. View at Google Scholar
  35. M. Kalani, “The importance of endothelin-1 for microvascular dysfunction in diabetes,” Vascular Health and Risk Management, vol. 4, no. 5, pp. 1061–1068, 2008. View at Google Scholar · View at Scopus
  36. I. V. Gorudko, V. A. Kostevich, A. V. Sokolov et al., “Increased myelopepoxidase activity is a risk factor for ishemic heart disease in patients with diabetes mellitus,” Biomeditsinskaya Khimiya, vol. 58, no. 4, pp. 475–484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Bhatia, R. Shukla, S. V. Madhu, J. K. Gambhir, and K. M. Prabhu, “Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy,” Clinical Biochemistry, vol. 36, no. 7, pp. 557–562, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. K. S. Weber, B. Nowotny, K. Strassburger et al., “The role of markers of low-grade inflammation for the early time course of glycemic control, glucose disappearance rate, and β-cell function in recently diagnosed type 1 and type 2 diabetes,” Diabetes Care, vol. 38, no. 9, pp. 1758–1767, 2015. View at Publisher · View at Google Scholar
  39. C. Gao, W. Huang, K. Kanasaki, and Y. Xu, “The role of ubiquitination and sumoylation in diabetic nephropathy,” BioMed Research International, vol. 2014, Article ID 160692, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. H. K. Koul, M. Pal, and S. Koul, “Role of p38 MAP kinase signal transduction in solid tumors,” Genes and Cancer, vol. 4, no. 9-10, pp. 342–359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. L. Gross, M. J. De Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz, “Diabetic nephropathy: diagnosis, prevention, and treatment,” Diabetes Care, vol. 28, no. 1, pp. 164–176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. J. Kang, W. Xiaoyan, L. Hao, K. Thai, and J. W. Scholey, “Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli,” Kidney International, vol. 55, no. 6, pp. 2203–2214, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. M. B. Duran-Salgado and A. F. Rubio-Guerra, “Diabetic nephropathy and inflammation,” World Journal of Diabetes, vol. 5, no. 3, pp. 393–398, 2014. View at Publisher · View at Google Scholar
  44. J. Wada and H. Makino, “Inflammation and the pathogenesis of diabetic nephropathy,” Clinical Science, vol. 124, no. 3, pp. 139–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Kanasaki, G. Taduri, and D. Koya, “Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis,” Frontiers in Endocrinology, vol. 4, article 7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Rysz, M. Banach, R. A. Stolarek et al., “Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy,” Journal of Nephrology, vol. 20, no. 4, pp. 444–452, 2007. View at Google Scholar · View at Scopus
  47. H. Cheng, X. Fan, G. W. Moeckel, and R. C. Harris, “Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1240–1251, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. I. Tossidou, G. Starker, J. Krüger et al., “PKC-alpha modulates TGF-β signaling and impairs podocyte survival,” Cellular Physiology and Biochemistry, vol. 24, no. 5-6, pp. 627–634, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. W. Qi, X. Chen, P. Poronnik, and C. A. Pollock, “The renal cortical fibroblast in renal tubulointerstitial fibrosis,” The International Journal of Biochemistry & Cell Biology, vol. 38, no. 1, pp. 1–5, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Pohlers, J. Brenmoehl, I. Löffler et al., “TGF-β and fibrosis in different organs—molecular pathway imprints,” Biochimica et Biophysica Acta, vol. 1792, no. 8, pp. 746–756, 2009. View at Publisher · View at Google Scholar · View at Scopus